The global death toll from noncommunicable diseases is exceptionally high, reported to cause 71% of global deaths worldwide. Metabolic syndrome risk factors, especially excessive adiposity and obesity, are at the heart of the problem resulting in increased comorbidities such as cardiometabolic diseases and cancer, increased health costs, poorer quality of life, and shortened survival. Vitamin D 3 can positively reverse many of these adverse effects and outcomes through blocking signaling mechanisms that predispose to cardiometabolic and metastatic disease. As an affordable natural agent, vitamin D 3 can be used to counteract obesity-induced inflammation, block early adipogenesis, enhance glucose uptake, counteract hyperleptinemia, ameliorate insulin resistance, and reduce hypertension. This is supported by data from in vitro, in vivo and epidemiological studies and clinical trials. We propose that everyone in general and obese patients in particular consider raising 25-hydroxyvitamin D levels through UVB exposure and/or supplemental vitamin D 3 intake to reduce cardiometabolic and metastatic disease and increase longevity.
Introduction
The metabolic syndrome is characterized by a number of inter-dependent risk factors or diseases that collectively increase a person's risk for developing type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs). These risk factors include elevated blood glucose levels, hypertension, dyslipidemia (specifically increased low--density lipoprotein (LDL) cholesterol, reduced high-density lipoprotein (HDL) cholesterol, and elevated triglycerides (TG)), increased fat mass and adiposity with intraabdominal fat accumulation, a large waist circumference and high waist to hip ratio. All of the above abnormalities lead to obesity, which is characterized by high body mass index (BMI) >30 kg/m 2 and increased adiposity. Obesity is also an independent risk factor of the metabolic syndrome and cardiometabolic diseases. 1 Obesity is thought to double the risk of co-morbidity and mortality from noncommunicable diseases (NCD) and their complications, including T2DM, CVDs, and cancer. 2, 3 This indicates a complex relationship among obesity, cardiometabolic diseases, T2DM, and cancer, 4 suggesting that many mechanistic regulatory pathways are common, perhaps intersecting, and may be collectively modulated in our search for therapeutic solutions.
At the intersection of all these diseases is increased adiposity and inflammation associated with increasing obesity levels.
with natural agents that can positively affect health, either through preventing risk factor occurrence, disease onset or pathological complications, via acting on several potentially intersecting metabolic pathways common to obesity, cardiometabolic diseases, and cancer. We propose below an argument for the use of vitamin D 3 for reduction of risk in obesity-associated NCD. How can we make this link? Epidemiological studies, which we review below, show that low circulating plasma levels of vitamin D 3 are present in obese individuals and are associated with poor morbidity and mortality outcomes from T2DM, CVD, and cancer. These have been shown to be ameliorated or reversed upon vitamin D 3 supplementation. Moreover, animal models indicate that vitamin D 3 is directly involved or implicated in adipogenesis and differentiation. Finally, mechanistic findings in vitro suggest that vitamin D 3 can simultaneously modulate several common intersecting hormone-regulated, obesity-induced, inflammation-potentiated signaling pathways common to T2DM, cardiometabolic diseases, and cancer. 2 As it is estimated that
Treatment of vitamin D deficiency on average costs less than 0.1% of the cost of investigations and treatment of worsening comorbidities and complications associated with hypovitaminosis D (ie, "vitamin D treatment cost of $12/year versus, average cost for managing complications, of $6,000 to 20,000/year per affected person"). 11 Then, vitamin D 3 supplementation appears to be a potentially suitable cost-effective preventive and therapeutic agent that should be considered for all individuals, and especially in obese patients or those diagnosed with established metabolic syndrome risk factors to improve health outcomes and survival.
Vitamin D metabolism and genomic action in the human body Adipose tissues are active endocrine tissues that regulate various biochemical and physiological processes involved in body homeostasis, glucose and lipid metabolism, adipokine secretion, appetite control, vascular remodeling, and insulin action. In both humans and rodents, it has been shown that adipose tissues have a high concentration of 25(OH)D and its metabolizing enzymes. 19, 23, 27 Obese individuals commonly store more vitamin D in adipose tissue than lean individuals. 28 Two rat model studies found support for effects of vitamin D in reducing the risk of metabolic syndrome, and by extension, risk of obesity. In one study, the combination of exercise and high-dose vitamin D reduced insulin, blood glucose, and homeostatic model assessment of insulin resistance (HOMA-IR). 29 In the other study, high-dose vitamin D supplementation significantly reduced weight, lipid profiles, visceral fat, and waist circumference of ovariectomized rats whether they were exercising or not. Vitamin D exerts a dose-dependent effect on adipocyte growth, differentiation, and survival Adipocytes from white adipose tissue (WAT) are some of the most resilient cells in humans and other animals. This is partly an evolutionary survival mechanism that animals have adopted over millions of years to allow for prolonged storage given a limitation of available food sources in the wild. In humans, however, changing social and behavioral transitions have led to a life of abundance over the last century, and this protective adaptive mechanism and adipocyte resilience against destruction has become a curse with food overconsumption. In turn, storage of excessive fat has become a cause of increased metabolic disease risk. Therefore, any agents or mechanisms that can promote enhanced β-oxidation of stored fatty acids or triglycerides or promote adipocyte apoptosis without increasing inflammation can be considered as potential candidates for fat mass reduction, obesity management, and consequent reduction of metabolic risk. From a mechanistic perspective, the effects of 1,25(OH) 2 D 3 on adipose tissues are conflicting and do not allow a clear conclusion to be drawn. The differences appear to change with several factors, including 1) absence or presence of VDR, 2) the concentration of 1,25(OH) 2 D 3 used in studies, 3) the species from which cells are derived, and (4) the stage of cell differentiation in which 1,25(OH) 2 D 3 is administered. 33, 34 In vitro studies in mouse-and human-derived cells have shown opposite effects depending on the source of cells and their differentiation stages. Treatment with low concentrations of 1,25(OH) 2 D 3 was found to inhibit adipogenesis in mouse 3T3-L1 cells in a time-limited and dose-dependent manner. 35 This inhibition was ineffective 36 Nobre et al confirmed that treatment of 3T3L1 preadipocytes, which are in the earlier stage of differentiation, with 1,25(OH) 2 D 3 decreases C/EBPα, PPARγ, and VDR protein levels, downregulates CYP7b1/1α-hydroxylase and VDR mRNA expression, and decreases cell proliferation and adipocyte number. However, co-culture with leptin decreased the ability of 1,25(OH) 2 D 3 to block adipogenesis in 3T3L1 preadipocytes co-cultured with both hormones. 37 Hyperleptinemia is known to be associated with increased adiposity and metabolic syndrome. Findings in animal models support the notion that vitamin D is related to energy metabolism and specifically fat mass. The VDR knockout mouse (VDR-/-mouse) presents a lean phenotype. Even upon high-fat feeding, these mice do not gain significant fat mass compared to wild-type animals. This VDR-/-phenotype is associated with increased levels of uncoupling proteins UCP-1, UCP-2, and UCP-3 in both BAT and WAT and an increased rate of β-oxidation in white adipose tissues. Both carnitine and carnitine palmitoyl transferase II responsible for transporting fatty acids into the mitochondrial matrix are increased in VDR-/-mice. 38 These data may suggest that VDR is an important factor for increasing adiposity and fat mass deposition. This increased adipose tissue formation sequesters plasma 25(OH)D and contributes to low circulating plasma levels and insufficiency.
Early research on 1,25(OH) 2 D 3 effects on apoptosis indicates that the hormone can exert a dose-dependent impact on adipocytes depending on their anatomical location and source by promoting glucocorticoid production and release. 39 In mature adipocytes, glucocorticoids may decrease lipid accumulation in differentiated adipocytes by promoting lipolysis and enhancing fatty acid mobilization, thus depleting the cell of its stored fats and sensitizing it to apoptosis. Additionally, treatment of mature mouse 3T3-L1 adipocytes induces Ca 2+ mediated apoptosis via activation of calpain and caspase-12. 40 In a diet-induced mouse model of obesity, dietary supplementation with high levels of vitamin D 3 , high calcium or high calcium plus vitamin D 3 resulted in a significantly lower body weight and reduced fat mass gain in mice fed high-fat diets compared to controls. This was associated with Ca 2+ dependent activation of apoptotic proteases in adipose tissues in mice given the supplementation. 41 The above finding supports the sugges- 46 Participants were given a bolus dose of 100,000 IU vitamin D 3 or placebo at outset, followed by 4000 IU/d or placebo thereafter for 16 weeks. In the treatment arm, mean 25(OH)D rose from 31 to 88 nmol/L. Differences between the treatment and control arms were not significant for insulin sensitivity or first-phase insulin secretion. However, an RCT conducted in Iran with 162 participants aged 18-80 years with baseline 25(OH)D =12.5 ng/ mL (31 nmol/L) conducted over a 6-month period did find a reduction in the vitamin D treatment arm. 43 Those in the vitamin D treatment arm were given 50,000 IU vitamin D 3 pearls once weekly for 3 months, followed by one pearl per month for the next 3 months. 25(OH)D rose from 13 to 41 ng/mL in the treatment arm and from 13 to 16 ng/mL in the control arm. The mean HOMA-IR score dropped from 3.4 to 2.9 and 2.6 after 3 and 6 months, respectively, in the treatment arm and from 3.4 to 3.1 after 3 and 6 months in the control arm, with P=0.04 for the difference between the two arms. Glucose tolerance was not significantly different between the two arms after 3 months (P=0.68) but did reach significance after 6 months (P=0.002). The primary difference between the two studies was duration, but the achieved 25(OH)D was also higher in the Iranian study. These two examples illustrate the problems inherent in conducting vitamin D RCTs.
In vitro, treatment with 1,25(OH) 2 D 3 improves 2-deoxyglucose uptake in 3T3-L1 adipocytes, implying a positive effect on glucose metabolism. Incubation of cells with 1,25 (OH) 2 D 3 for 24 hrs results in a fourfold increase in insulinstimulated uptake of 2-deoxyglucose in 3T3-L1 adipocytes compared to controls. Moreover, cells pre-treated with 1,25 (OH) 2 D 3 and then challenged with pro-inflammatory TNF-α had a 40% higher uptake of 2-deoxyglucose compared to those suppressed in their response to insulin stimulation following TNF-α treatment alone. Treatment with 1,25 (OH) 2 D 3 counteracted the effect of TNF-α and restored glucose uptake response close to normal function (90%). The effect of 1,25(OH) 2 D 3 was mediated by AKT phosphorylation. 47 These results have a huge implication for the recommended use of vitamin D 3 in diabetic, insulinresistant and obese patients to improve sensitization to insulin and promote glucose uptake as part of therapeutic protocols.
In an insulin-resistant cell model (IR BeWo model) exhibiting high inflammatory gene expression and elevated mTOR signaling, treatment with 1,25(OH) 2 VitaminD 3 reversed mTOR activation and reduced IR levels and lipid infiltration while decreasing leptin, TNF-α, and IL-6 levels. 48 In another diet-induced obesity model, mice fed high levels of vitamin D 3 , high calcium or high calcium plus vitamin D 3 all had lower plasma concentrations of glucose and insulin along with increased levels of adiponectin, the hormone that sensitizes adipocytes to insulin. 41 Upon vitamin D 3 supplementation, with or without Ca, 2+ the decrease in plasma insulin concentrations was almost completely normalized to concentrations measured in controls. Collectively, if animal model findings can be extrapolated to humans, these data may indicate that in vivo dietary supplementation of vitamin D 3 may attenuate diet-induced hyperglycemia, increase insulin sensitivity and action, and prevent postprandial hyperinsulinemia if administered to obese individuals. Hyperinsulinemia, present in insulin-resistant, diabetic and obese individuals can pose a secondary health risk by potentiating the incidence of disorders such as polycystic ovary syndrome and cancer, as well as increasing mortality.
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Vitamin D's effect on obesityinduced inflammation
Obesity is associated with increased inflammation. 50 Adipocytes can secrete IL-6, which is a major inflammatory mediator in obesity. IL-6 also downregulates adiponectin, an anti-inflammatory adipokine. Decreased adiponectin is associated with increased pro-inflammatory effects associated with NF-κB activation. 51 Increased IL-6 concentrations and inflammation are associated with IR and a risk of T2DM and CVD. In vitro studies show that treatment of lipopolysaccharide (LPS)-stimulated mouse 3T3-L1 adipocytes with 1,25 (OH) 2 D 3 for 24 hrs significantly decreased IL-6 production but had no effect on IL-10 production. Similarly, a reduction in IL-6 production in epididymal WAT was observed in mice fed high-fat diets supplemented with vitamin D 3 compared to controls. The in vivo findings in mice are especially promising, as they indicate that vitamin D 3 can be considered as an adjuvant to reduce inflammation in obese subjects. 52 Similarly, in human adipocytes from two different sources -bone marrow-derived human mesenchymal stromal cells (hMSCs) differentiated into adipocytes and adipocytes isolated from biopsies stimulated with LPS -24-hr treatment with 1,25(OH) 2 D 3 resulted in a significant reduction in IL-6 secretion. This was associated with a reduction in nuclear factor-κB (NF-ĸB) nuclear translocation and activity. 53 Treatment with 1,25(OH) 2 D 3 can reduce pro-inflammatory effects induced by TNF-α in 3T3-L1 adipocytes and adipocyte-macrophage co-cultures. This attenuation of the inflammatory response is mediated by dephosphorylation of mitogen activated protein kinase p38, downregulation of NF-ĸB, and induction of dual-specificity phosphatases (DUSP) DUSP 1, 10, 11 and 16. 47 Human adipocytes pre-sensitized with IL-1β and treated with 1,25(OH) 2 D 3 showed a significant reduction in mRNA levels of pro-inflammatory interleukins IL-6, IL-8 and monocyte chemoattractant protein-1 (MCP-1), along with reduced IL-8 secretion. However, a similar reduction was not observed in adipose tissue biopsies removed from obese subjects receiving an oral treatment of vitamin D 3 (7000 IU). 54 Observational studies do not lend compelling evidence to support an effect of vitamin D on inflammatory markers in metabolic syndrome patients. There is only weak evidence from observational studies to show that vitamin D reduces biomarkers of inflammation. For example, an RCT involving overweight/obese adults given high-dose vitamin D for 16 weeks did not find any significant reductions in inflammatory biomarkers. 46 However, RCTs involving participants with various diseases have found beneficial effects, such as for T2DM 55, 56 and polycystic ovary syndrome.
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A meta-analysis investigated the effects of vitamin D supplementation on biomarkers of inflammation and oxidative stress in patients with different forms of DM. 55 
Vitamin D regulates circulating lipids, blood pressure and improves CVD outcomes
The endothelium plays an important role in the maintenance of blood fluidity, vessel wall tone and permeability. Endothelial damage via oxidative stress and metabolic disorders contributes to vascular endothelial dysfunction, impaired vascular relaxation, vascular hypertrophy fibrosis, plaque deposition, and arterial stiffness, all of which contribute to hypertension, atherosclerosis and CVDs. 58, 59 Obesity-associated hyperleptinemia has been shown to cause endothelial cell dysfunction and increase inflammation and oxidative stress in vitro and in vivo. 60, 61 Obese individuals have been reported to have significantly higher plasma leptin levels compared to eutrophic individuals. 62 Most recently, plasma leptin level has been reported to be positively associated with increased blood pressure independent of gender and BMI. 63 Recent findings demonstrate that 1,25
(OH) 2 D 3 can counteract leptin-induced oxidative stress and inflammation in human umbilical vein endothelial cells. Treatment of these cells with leptin alone significantly increased reactive oxygen species production, NF-κB translocation to the nucleus, and upregulated the mRNA expression of MCP1, TGFβ, and vascular adhesion molecule 1. Pretreatment with 1,25(OH) 2 D 3 at physiological concentrations (10 -10 M) and supraphysiological concentrations (10
M) prevented leptin-induced superoxide anion production, significantly increased nuclear factor (erythroid-derived 2)-like 2 (NRF2) translocation to the nucleus, and upregulated expression of the antioxidant defense genes superoxide dismutase 2, glutathione peroxidase, NADPH hydrogenase (quinone) 1 (NQO1), and heme oxygenase 1. 64 These findings reinforce the idea that 1,25(OH) 2 D 3 may have potent protective effects against oxidative stress-induced damage and hence prevent metabolic complications of obesity such as hypertension or other inflammation-induced complications mediated by increased NFκB activity. VDR-null mice display less body fat mass and lower plasma triglyceride and cholesterol levels compared with wild-type male mice. 38 VDR-/-mice also have higher blood pressure than wild-type mice. These effects are associated with increases in renin (RER) mRNA expression and plasma angiotensin II. These mice remain responsive to challenges in salt variation, though not as effectively as wild-type controls, indicating that VDR plays a role in the renin-angiotensin system and ultimately in blood pressure control. At the gene level, the renin gene RER contains a transcription response element that can be repressed by VDR binding. 65, 66 Mice with a deletion in VDR also exhibit a reduction in end-diastolic and end-systolic volume, impaired ventricular function and cardiac hypertrophy due to increased calcineurin inhibitory protein 1 expression (MCIP1) and impairments in the calcineurin/nuclear factor of activated T cell (NFATc1) signaling pathways. 70 Perhaps the latter may be due to the effects of vitamin D on increased lipolysis in adipocytes and β-oxidation associated with concentrated vitamin action on WAT. However, further studies need to be conducted in this respect and should include male subjects to confirm the mechanisms explaining the dose-dependent effects.
As for observational studies, there is limited evidence that vitamin D reduces blood pressure and hypertension. In a 6-month vitamin D supplementation study involving middleaged African Americans, each 1 ng/mL increase in 25(OH)D resulted in a significant 0.2 mm Hg drop in systolic blood pressure (SBP) but no effect on diastolic blood pressure (DBP). 71 In a community-based open-label study in Canada where participants were provided vitamin D 3 supplements and encouraged to achieve >40 ng/mL 25(OH)D, those who were hypertensive at baseline (SBP~155 mm Hg, DBP~95 mm Hg) reduced their SBP by~14-18 mm Hg and DBP bỹ 12 mm Hg. 72 However, participants who were prehypertensive did not have significant reductions in blood pressure. However, in CVD outcomes, there is reasonable evidence that vitamin D reduces the risk of CVD. A meta-analysis of 34 prospective observational studies involving 180,667 participants found that the pooled risk ratio for the incidence of a 10-ng/mL increase was 0.90 (95% CI, 0.86-0.94), while the risk ratio for mortality was 0.88 (95% CI, 0.80-0.96).
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A meta-analysis of the effects of vitamin D supplementation on CVD risk factors based on 81 studies found significant beneficial effects for blood pressure, lipid profile, parathyroid hormone, and serum high-sensitivity Creactive protein (hs-CRP) but not for peak wave velocity or augmentation index. 74 Additional evidence that vitamin D deficiency plays an important role in the risk of CVD is that CVD rates are 15-25% higher in winter than in summer, 75 even in warm countries such as Kuwait. 76 In general, a majority of the evidence points to a beneficial effect of vitamin D in reducing the risk of CVD, although RCTs are not available to support these associations. 77, 78 For example, the VITAL study found a 
Vitamin D reduces risk of and improves survival from cancer
There is very strong evidence that vitamin D reduces the risk of incidence and death for many types of cancer. Geographical ecological studies from mid-latitude countries generally find inverse correlations between indices of solar UVB doses and mortality rates for 15-20 types of cancer.
14 Prospective observational studies have found significant inverse correlations between serum 25(OH)D at the time of enrollment and incidence of colorectal cancer. 80 Case-control studies have identified a significant inverse correlation between 25(OH)D measured near time of diagnosis, but this correlation was not observed in prospective studies due to the fact that breast cancer can develop rapidly. 81 Vitamin D is more effective at reducing cancer mortality rates than incidence rates. For example, a meta-analysis of the effects of vitamin D supplementation on risk of cancer found no significant effect on cancer incidence but a significant 15% reduction in cancer mortality rates. 82 The mechanisms whereby vitamin D reduces the risk of cancer are well known. The most important of these affect cellular differentiation, proliferation and apoptosis, angiogenesis, and metastasis. 14, 83, 84 Recently, results of the VITAL trial were released. 26 This RCT included over 25,000 participants, including more than 5000 African Americans, who were followed for 5 years. 
Conclusion and recommendations for improved metabolic health and wellbeing
We propose the use of vitamin D 3 for all individuals to protect against cardiometabolic and metastatic disease ( Table 2) . In vitro studies, animal models, observational studies' findings, and limited number of existing RCTs support the proposal that vitamin D 3 will have therapeutic power/benefits to reduce the burden of disease in obese patients by counteracting the effects of many metabolic risk factors. This will greatly improve patient health outcomes, quality of life, and survival. This is expected to reduce health costs of treating NCDs, related comorbidities, and associated indirect loss of productivity costs. Overall, the cost of a maintenance dose of 1000-5000 IU vitamin D 3 daily needed to achieve plasma circulating levels in the range of 30-50 ng/mL is cost-effective compared to costs of treatment of NCDs. In addition, there are many additional health benefits of vitamin D supplementation and very limited risk of adverse effects. Given that increased adiposity has the effect of depleting much of the 25(OH)D precursor out of the plasma, 85 the higher daily dose of vitamin D 3 is advised in obese individuals. More RCTs need to be conducted in obese patients to determine the correct daily dose-titration needed in patients with increasing number of metabolic risk factors or increasing disease severity.
Disclosure
Dr William B Grant reports grants from Bio-Tech Pharmacal, Inc., outside the submitted work. The authors report no other conflicts of interest in this work.
